355 related articles for article (PubMed ID: 26469193)
21. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
22. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
23. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Trujillo-Santos J; Nieto JA; Tiberio G; Piccioli A; Di Micco P; Prandoni P; Monreal M;
Thromb Haemost; 2008 Sep; 100(3):435-9. PubMed ID: 18766259
[TBL] [Abstract][Full Text] [Related]
24. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
25. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis.
Piran S; Le Gal G; Wells PS; Gandara E; Righini M; Rodger MA; Carrier M
Thromb Res; 2013 Nov; 132(5):515-9. PubMed ID: 24035045
[TBL] [Abstract][Full Text] [Related]
26. Treating patients with cancer and acute venous thromboembolism.
Donadini MP; Squizzato A; Ageno W
Expert Opin Pharmacother; 2016; 17(4):535-43. PubMed ID: 26606049
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and meta-analysis of the incidence of post-thrombotic syndrome, recurrent thromboembolism, and bleeding after upper extremity vein thrombosis.
Espitia O; Raimbeau A; Planquette B; Katsahian S; Sanchez O; Espinasse B; Bénichou A; Murris J
J Vasc Surg Venous Lymphat Disord; 2024 Jan; 12(1):101688. PubMed ID: 37717788
[TBL] [Abstract][Full Text] [Related]
28. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
Sindet-Pedersen C; Langtved Pallisgaard J; Staerk L; Gerds TA; Fosbøl EL; Torp-Pedersen C; Gislason G; Olesen JB
Thromb Haemost; 2017 Jun; 117(6):1182-1191. PubMed ID: 28300865
[TBL] [Abstract][Full Text] [Related]
29. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
[TBL] [Abstract][Full Text] [Related]
30. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
31. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
33. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
34. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.
van der Hulle T; den Exter PL; Kooiman J; van der Hoeven JJ; Huisman MV; Klok FA
J Thromb Haemost; 2014 Jul; 12(7):1116-20. PubMed ID: 24819040
[TBL] [Abstract][Full Text] [Related]
36. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
[TBL] [Abstract][Full Text] [Related]
38. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
39. Safety of anticoagulant treatment in cancer patients.
Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
